ATE216593T1 - Modulation der immunantwort - Google Patents

Modulation der immunantwort

Info

Publication number
ATE216593T1
ATE216593T1 AT95939341T AT95939341T ATE216593T1 AT E216593 T1 ATE216593 T1 AT E216593T1 AT 95939341 T AT95939341 T AT 95939341T AT 95939341 T AT95939341 T AT 95939341T AT E216593 T1 ATE216593 T1 AT E216593T1
Authority
AT
Austria
Prior art keywords
molecules
immunogen
administration
immune response
ligands
Prior art date
Application number
AT95939341T
Other languages
English (en)
Inventor
Douglas Thomas Fearon
Paul Walter Dempsey
Original Assignee
Univ Cambridge Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cambridge Tech filed Critical Univ Cambridge Tech
Application granted granted Critical
Publication of ATE216593T1 publication Critical patent/ATE216593T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Optical Communication System (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicinal Preparation (AREA)
AT95939341T 1994-12-06 1995-12-06 Modulation der immunantwort ATE216593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424631A GB9424631D0 (en) 1994-12-06 1994-12-06 Modulating the immune response
PCT/GB1995/002851 WO1996017625A1 (en) 1994-12-06 1995-12-06 Modulating the immune response

Publications (1)

Publication Number Publication Date
ATE216593T1 true ATE216593T1 (de) 2002-05-15

Family

ID=10765518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939341T ATE216593T1 (de) 1994-12-06 1995-12-06 Modulation der immunantwort

Country Status (12)

Country Link
US (2) US6238670B1 (de)
EP (1) EP0797452B1 (de)
JP (1) JPH10509723A (de)
AT (1) ATE216593T1 (de)
AU (1) AU709990B2 (de)
CA (1) CA2207000A1 (de)
DE (1) DE69526521T2 (de)
DK (1) DK0797452T3 (de)
ES (1) ES2176347T3 (de)
GB (1) GB9424631D0 (de)
PT (1) PT797452E (de)
WO (1) WO1996017625A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734196B2 (en) 1996-03-28 2001-06-07 Whitehead Institute Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
EP0996717B1 (de) * 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunschützendes influenzaantigen und dessen verwendung zur impfung
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
GB9727512D0 (en) 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
AU762799B2 (en) * 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
EP1001021B1 (de) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoklonaler Antikörper gegen das humanen CD21 und dessen Verwendungen
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001092295A2 (en) * 2000-05-30 2001-12-06 University Of Toronto Ligands for cd21 and compositions thereof for modulating immune responses
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
CN1511041A (zh) * 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
WO2004016283A2 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
JP2004222435A (ja) * 2003-01-16 2004-08-05 Fuji Heavy Ind Ltd 電気自動車の駆動装置
WO2013110064A1 (en) * 2012-01-19 2013-07-25 Albany Medical College Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
US10040827B2 (en) 2012-03-19 2018-08-07 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing T-cell epitopes
EP2674168A1 (de) * 2012-06-14 2013-12-18 PLS-Design GmbH Modulation von Effektor-T-Zell-Antworten durch lokale Depletion des Komplement-Faktors C3
WO2014006063A2 (en) 2012-07-02 2014-01-09 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
JP2020533414A (ja) 2017-09-11 2020-11-19 インサイドアウトバイオ インコーポレイテッド 腫瘍の免疫原性を増強する方法および組成物
WO2020092140A2 (en) 2018-11-02 2020-05-07 Insideoutbio, Inc. Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products
WO2023090771A1 (ko) * 2021-11-17 2023-05-25 대한민국(농림축산식품부 농림축산검역본부장) 강력한 적응성 면역반응 유도 및 모체이행항체의 간섭을 극복하는 재조합 구제역 o형 바이러스 및 이를 포함하는 구제역 백신 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2023779A1 (en) * 1989-08-23 1991-02-24 Margaret D. Moore Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
WO1991013974A1 (en) * 1990-03-14 1991-09-19 The Biomembrane Institute Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Also Published As

Publication number Publication date
US6238670B1 (en) 2001-05-29
US20020102656A1 (en) 2002-08-01
WO1996017625A1 (en) 1996-06-13
EP0797452A1 (de) 1997-10-01
ES2176347T3 (es) 2002-12-01
US6891027B2 (en) 2005-05-10
AU4120496A (en) 1996-06-26
DK0797452T3 (da) 2002-08-19
DE69526521D1 (de) 2002-05-29
DE69526521T2 (de) 2002-12-05
PT797452E (pt) 2002-10-31
CA2207000A1 (en) 1996-06-13
EP0797452B1 (de) 2002-04-24
GB9424631D0 (en) 1995-01-25
AU709990B2 (en) 1999-09-09
JPH10509723A (ja) 1998-09-22

Similar Documents

Publication Publication Date Title
DE69526521D1 (de) Modulation der immunantwort
DE68924850D1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
ATE47155T1 (de) Monoklonaler antikoerper.
DK338587D0 (da) Modulsamling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20003716D0 (no) Protein D for anvendelse in vitro, renset antistoff som binder proteinet, samt anvendelser derav
EP0699907A3 (de) Diagnoseverfahren, lösliches CD8-T-Zelloberflächenantigen und anti-CD8-Antikörper
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
IE811595L (en) Synthetic peptide antigens
AU3900589A (en) Antigenic constructs of major histocompatibility complex class 1 antigens with specific carrier molecules, the preparation and use thereof
RU93058563A (ru) Полипептиды, иммунореагент, способ определения антител, способ индукции иммунного ответа, композиции, способ получения полипептида
ES2181734T3 (es) Ensayo inmunologico de ciclosporina.
SE9103183L (sv) Virus-antikroppskomplex
ES2045216T3 (es) Inmunoensayo y derivados polimeros de igg para la compensacion de factores de perturbacion en el inmunoensayo.
WO1998025958A3 (en) Mammalian cell surface antigens comprising structural motifs characteristic of a member of the TNF ligand family
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
ATE45285T1 (de) Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
IT8720842A0 (it) Analisi immunologiva stratificata impiegando anticorpi legati a particelle di trasporto per determinare la presenza di un antigene.
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
EP0363109A3 (de) Bestimmung eines chlamydialen oder gonokokkalen Antigens unter Verwendung eines positiv geladenen ionischen Bindungsträgers
JPS5533474A (en) Vaccine and its manufacture
ATE87941T1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
DK635388D0 (da) Immobiliserede antistoffer
EP0158291A3 (de) Verfahren zur Reinigung von karzinoembryonischem Antigen und Verfahren zur Herstellung eines monoklonalen Antikörpers, der mit karzinoembryonischem Antigen reagiert
DK528279A (da) Fremgangsmaade til isolering af hepatitis b e antigen eller antistof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee